Stanislaw Chorzepa, DO
Internal Medicine · Kensington, CTNPI 1750375127
Payments from drug & device makers
Across 326 payments — averaging $16.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$883
- Pfizer$514
- Lilly USA, LLC$484
- Boehringer Ingelheim$419
- Novo Nordisk$336
- plus $2K from 27 others
What the payments were for
- Food & beverage$5,463100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 69 | $1,126 |
| AstraZeneca | 57 | $883 |
| Pfizer | 31 | $514 |
| Lilly USA, LLC | 27 | $484 |
| Boehringer Ingelheim | 23 | $419 |
| Novo Nordisk | 21 | $336 |
| Johnson & Johnson | 11 | $172 |
| Phathom Pharmaceuticals, Inc. | 10 | $162 |
| Sanofi-aventis U.S. LLC | 10 | $148 |
| Esperion Therapeutics, Inc. | 2 | $137 |
| Amgen(2 entities) | 6 | $97 |
| Boston Scientific | 3 | $93 |
| Eisai Inc. | 6 | $85 |
| GSK | 4 | $77 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $76 |
| Genentech USA, Inc. | 4 | $69 |
| Bayer | 3 | $66 |
| Novartis | 3 | $60 |
| Idorsia Pharmaceuticals US Inc | 4 | $59 |
| Exact Sciences | 3 | $54 |
| Merck | 3 | $45 |
| E.r. Squibb & Sons, L.L.C. | 3 | $44 |
| Kowa Pharmaceuticals America, Inc. | 3 | $43 |
| Abbott | 3 | $42 |
| Amarin Pharma, Inc. | 2 | $33 |
| Otsuka America Pharmaceutical, Inc. | 2 | $29 |
| Arbor Pharmaceuticals, Inc. | 2 | $27 |
| Hikma Pharmaceuticals USA | 2 | $23 |
| Medtronic | 1 | $19 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| Assertio Therapeutics, Inc. | 1 | $13 |
| Eyevance Pharmaceuticals LLC | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,474 in reported general payments places this provider in the 90th percentile of 2,067 internal medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 152 | $196,002 |
| MounjaroTirzepatide | 64 | $76,604 |
| JardianceEmpagliflozin | 62 | $72,473 |
| EliquisApixaban | 43 | $56,971 |
| FarxigaDapagliflozin Propanediol | 35 | $50,981 |
| GlyxambiEmpagliflozin/Linagliptin | 33 | $31,682 |
| JanuviaSitagliptin Phosphate | 20 | $31,519 |
| LinzessLinaclotide | 22 | $30,378 |
| XareltoRivaroxaban | 17 | $29,038 |
| MyrbetriqMirabegron | 16 | $12,217 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 11 | $9,644 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $6,199 |
| Varenicline Tartrate | 32 | $6,116 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $4,369 |
| Rosuvastatin Calcium | 508 | $3,944 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $336 | $196,002152 claims |
| Boehringer IngelheimJardiance, Glyxambi | $419 | $104,15595 claims |
| Lilly USA, LLCMounjaro | $484 | $76,60464 claims |
| PfizerEliquis | $514 | $56,97143 claims |
| AstraZenecaFarxiga, Symbicort | $883 | $55,35048 claims |
| AbbVieLinzess, Synthroid | $1,126 | $34,04153 claims |
| MerckJanuvia | $45 | $31,51920 claims |
| Johnson & JohnsonXarelto | $172 | $29,03817 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $148 | $9,64411 claims |
| GSKBreo Ellipta | $77 | $6,19911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,067 internal medicine providers in Connecticut.
Other internal medicine in Kensington
- Joseph SouferWaterbury$21.5M
- David RadinStamford$7M
- Steven RyderWestport$3.9M
- Nancy BrownNew Haven$2.8M
- Charles MontanoCromwell$2.8M
- Arthur DecillisMadison$1M
- Michelle MallitzTrumbull$971K
- Allen HellerWoodbridge$758K
- Gary BlickNorwalk$717K
- Margaret ChusteckaHamden$652K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.